English

Amryt Pharma plc

EDGAR

AMYT Report (type unavailable) · filed 2023-04-12

59 filing records in this dataset, filed from 2020-06-23 to 2023-04-12. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest fiscal year

Revenue

223 million U002

2021 · U002

Exact inputs and evidence

Revenue: 222543000 U002 Source

Operating margin

-17.34%

2021 · %

Exact inputs and evidence

Operating Income: -38588000 U002 Source
Revenue: 222543000 U002 Source

Operating cash flow

15.5 million U002

2021 · U002

Exact inputs and evidence

Operating Cash Flow: 15540000 U002 Source

Free cash flow

14.8 million U002

2021 · U002

Exact inputs and evidence

Operating Cash Flow: 15540000 U002 Source
Capital Expenditure: 729000 U002 Source

Cash and cash equivalents: 113 million U002 2021-12-31 Source
Exact value

113032000 U002
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2023-04-12.

Financial data available through: 2021-12-31.

Coverage by financial measure

Revenue: 4 of 11 periods available· newest 2021-12-31
Operating income: 4 of 11 periods available· newest 2021-12-31
net income: No compatible figures in this window
Operating cash flow: 4 of 11 periods available· newest 2021-12-31
Capital expenditure: 4 of 11 periods available· newest 2021-12-31
Total assets: 3 of 11 periods available· newest 2021-12-31
Total liabilities: 3 of 11 periods available· newest 2021-12-31
Current assets: 3 of 11 periods available· newest 2021-12-31
Current liabilities: 3 of 11 periods available· newest 2021-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2021-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+21.9%

Prior period

U002 182.61 million

2020-01-01 – 2020-12-31
Current period

U002 222.54 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

222543000 − 182607000 = 39936000 U002

182607000 U002 · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
222543000 U002 · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Amryt Pharma plc · 2021-12-31 Amryt Pharma plc (edgar:1783010) Year-over-year change in Revenue: 39936000 U002 Concept: fundies:Revenue Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:26:28Z Snapshot: 38c0edc4ea668d290f812b45724871aa835a6a18bf39ab3bcb7b4c9043e6665b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783010?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 222543000 U002 (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783010/000114036122016877/brhc10036778_20f.htm#3482412 Filing: 000114036122016877 Input fundies:Revenue: 182607000 U002 (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783010/000114036122016877/brhc10036778_20f.htm#3506731 Filing: 000114036122016877
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
-42.2%

Prior period

U002 26.89 million

2020-01-01 – 2020-12-31
Current period

U002 15.54 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

15540000 − 26891000 = -11351000 U002

26891000 U002 · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
15540000 U002 · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Amryt Pharma plc · 2021-12-31 Amryt Pharma plc (edgar:1783010) Year-over-year change in Operating cash flow: -11351000 U002 Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:26:28Z Snapshot: 38c0edc4ea668d290f812b45724871aa835a6a18bf39ab3bcb7b4c9043e6665b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783010?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 15540000 U002 (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783010/000114036122016877/brhc10036778_20f.htm#2411739 Filing: 000114036122016877 Input fundies:OperatingCashFlow: 26891000 U002 (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783010/000114036122016877/brhc10036778_20f.htm#2412873 Filing: 000114036122016877
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-51.5%

Prior period

U002 1.5 million

2020-01-01 – 2020-12-31
Current period

U002 729,000

2021-01-01 – 2021-12-31

Exact inputs and evidence

729000 − 1503000 = -774000 U002

1503000 U002 · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
729000 U002 · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Amryt Pharma plc · 2021-12-31 Amryt Pharma plc (edgar:1783010) Year-over-year change in Capital expenditure: -774000 U002 Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:26:28Z Snapshot: 38c0edc4ea668d290f812b45724871aa835a6a18bf39ab3bcb7b4c9043e6665b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783010?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 729000 U002 (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783010/000114036122016877/brhc10036778_20f.htm#2424942 Filing: 000114036122016877 Input fundies:CapitalExpenditure: 1503000 U002 (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783010/000114036122016877/brhc10036778_20f.htm#2426040 Filing: 000114036122016877
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Net income.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2021 2021-01-01 – 2021-12-31

Revenue U002 222.54 million 100% of revenue
Cost of revenue U002 106.12 million 48% of revenue
Operating expenses U002 129.72 million 58% of revenue
Other operating costs Derived U002 25.29 million 11% of revenue
Operating income −U002 38.59 million −17% of revenue
Tax, interest and other Derived Unavailable An input is unavailable.
Net income Unavailable An input is unavailable.

Cash

Operating cash flow U002 15.54 million 7% of revenue
Capital expenditure U002 729,000 0.3% of revenue
Free cash flow Derived U002 14.81 million 6.7% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2018 Not shown: operating income or net income is not reported.
2019 Not shown: operating income or net income is not reported.
2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2018 2018-01-01 – 2018-12-31	17095000	35132000 Derived	-18037000	Unavailable	Unavailable	-15534000 Derived	Source 2018-01-01 – 2018-12-31: 17095000 U002 Inspect Revenue Open source 2018-01-01 – 2018-12-31: -18037000 U002 Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -15454000 U002 Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 80000 U002 Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	58124000	108607000 Derived	-50483000	Unavailable	Unavailable	-38050000 Derived	Source 2019-01-01 – 2019-12-31: 58124000 U002 Inspect Revenue Open source 2019-01-01 – 2019-12-31: -50483000 U002 Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -37472000 U002 Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 578000 U002 Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	182607000	229066000 Derived	-46459000	Unavailable	Unavailable	25388000 Derived	Source 2020-01-01 – 2020-12-31: 182607000 U002 Inspect Revenue Open source 2020-01-01 – 2020-12-31: -46459000 U002 Inspect Operating Income Open source 2020-01-01 – 2020-12-31: 26891000 U002 Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 1503000 U002 Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	222543000	261131000 Derived	-38588000	Unavailable	Unavailable	14811000 Derived	Source 2021-01-01 – 2021-12-31: 222543000 U002 Inspect Revenue Open source 2021-01-01 – 2021-12-31: -38588000 U002 Inspect Operating Income Open source 2021-01-01 – 2021-12-31: 15540000 U002 Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 729000 U002 Inspect Capital Expenditure Open source

Amounts are exact, in U002.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

U002 222.5M 2021

Values and sources

Revenue values and source evidence
Period	Series	Value(U002)	Source evidence
20182018-12-31	Revenue	17095000	Revenue: 17095000 Open source
20192019-12-31	Revenue	58124000	Revenue: 58124000 Open source
20202020-12-31	Revenue	182607000	Revenue: 182607000 Open source
20212021-12-31	Revenue	222543000	Revenue: 222543000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

21.9% 2021

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Year over year	No prior comparable period	Revenue: 17095000 Open source
20192019-12-31	Year over year	240%	Revenue: 58124000 Open source Revenue: 17095000 Open source
20202020-12-31	Year over year	214.2%	Revenue: 182607000 Open source Revenue: 58124000 Open source
20212021-12-31	Year over year	21.9%	Revenue: 222543000 Open source Revenue: 182607000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -17.3% 2021

Free cash flow margin 6.7% 2021

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Operating margin	-105.5%	Operating Income: -18037000 Open source Revenue: 17095000 Open source
20192019-12-31	Operating margin	-86.9%	Operating Income: -50483000 Open source Revenue: 58124000 Open source
20202020-12-31	Operating margin	-25.4%	Operating Income: -46459000 Open source Revenue: 182607000 Open source
20212021-12-31	Operating margin	-17.3%	Operating Income: -38588000 Open source Revenue: 222543000 Open source
2018-12-31	Net margin	Not reported	Revenue: 17095000 Open source
2019-12-31	Net margin	Not reported	Revenue: 58124000 Open source
2020-12-31	Net margin	Not reported	Revenue: 182607000 Open source
2021-12-31	Net margin	Not reported	Revenue: 222543000 Open source
20182018-12-31	Free cash flow margin	-90.9%	Revenue: 17095000 Open source Operating Cash Flow: -15454000 Open source Capital Expenditure: 80000 Open source
20192019-12-31	Free cash flow margin	-65.5%	Revenue: 58124000 Open source Operating Cash Flow: -37472000 Open source Capital Expenditure: 578000 Open source
20202020-12-31	Free cash flow margin	13.9%	Revenue: 182607000 Open source Operating Cash Flow: 26891000 Open source Capital Expenditure: 1503000 Open source
20212021-12-31	Free cash flow margin	6.7%	Revenue: 222543000 Open source Operating Cash Flow: 15540000 Open source Capital Expenditure: 729000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

U002 15.5M 2021

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(U002)	Source evidence
20182018-12-31	Operating cash flow	-15454000	Operating Cash Flow: -15454000 Open source
20192019-12-31	Operating cash flow	-37472000	Operating Cash Flow: -37472000 Open source
20202020-12-31	Operating cash flow	26891000	Operating Cash Flow: 26891000 Open source
20212021-12-31	Operating cash flow	15540000	Operating Cash Flow: 15540000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

U002 14.8M 2021

Values and sources

Free cash flow values and source evidence
Period	Series	Value(U002)	Source evidence
20182018-12-31	Free cash flow	-15534000	Operating Cash Flow: -15454000 Open source Capital Expenditure: 80000 Open source
20192019-12-31	Free cash flow	-38050000	Operating Cash Flow: -37472000 Open source Capital Expenditure: 578000 Open source
20202020-12-31	Free cash flow	25388000	Operating Cash Flow: 26891000 Open source Capital Expenditure: 1503000 Open source
20212021-12-31	Free cash flow	14811000	Operating Cash Flow: 15540000 Open source Capital Expenditure: 729000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

56.3% 2021

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2018-12-31	Liabilities / assets	Not reported	No source recorded
20192019-12-31	Liabilities / assets	75%	Total Liabilities: 395263000 Open source Total Assets: 527096000 Open source
20202020-12-31	Liabilities / assets	87.7%	Total Liabilities: 470449000 Open source Total Assets: 536591000 Open source
20212021-12-31	Liabilities / assets	56.3%	Total Liabilities: 459396000 Open source Total Assets: 816057000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

1.8× 2021

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2018-12-31	Current assets / current liabilities	Not reported	No source recorded
20192019-12-31	Current assets / current liabilities	1.57×	Current Assets: 160729000 Open source Current Liabilities: 102226000 Open source
20202020-12-31	Current assets / current liabilities	2.01×	Current Assets: 202975000 Open source Current Liabilities: 101175000 Open source
20212021-12-31	Current assets / current liabilities	1.8×	Current Assets: 282709000 Open source Current Liabilities: 157279000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2018 2018-01-01 – 2018-12-31	Unavailable Not reported for this period.	−U002 15.45 million Exact value Exact value: -15454000 U002 2018-01-01 – 2018-12-31: -15454000 U002 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Amryt Pharma plc · 2018-12-31 Amryt Pharma plc (edgar:1783010) Operating Cash Flow: -15454000 U002 Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T21:26:28Z Snapshot: 38c0edc4ea668d290f812b45724871aa835a6a18bf39ab3bcb7b4c9043e6665b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783010/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=U002&dimensions= Input fundies:OperatingCashFlow: -15454000 U002 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783010/000114036121015121/amyt-20201231.xml#495793 Filing: 000114036121015121 The citation records this snapshot. The page link may show a newer release later.	U002 80,000 Exact value Exact value: 80000 U002 2018-01-01 – 2018-12-31: 80000 U002 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Amryt Pharma plc · 2018-12-31 Amryt Pharma plc (edgar:1783010) Capital Expenditure: 80000 U002 Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T21:26:28Z Snapshot: 38c0edc4ea668d290f812b45724871aa835a6a18bf39ab3bcb7b4c9043e6665b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783010/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=U002&dimensions= Input fundies:CapitalExpenditure: 80000 U002 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783010/000114036121015121/amyt-20201231.xml#2482693 Filing: 000114036121015121 The citation records this snapshot. The page link may show a newer release later.	−U002 15.53 million Calculation and evidence -15454000 − 80000 U002 Exact free cash flow: -15534000 U002 2018-01-01 – 2018-12-31: -15454000 U002 · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 80000 U002 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Amryt Pharma plc · 2018-12-31 Amryt Pharma plc (edgar:1783010) Free cash flow: -15534000 U002 Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T21:26:28Z Snapshot: 38c0edc4ea668d290f812b45724871aa835a6a18bf39ab3bcb7b4c9043e6665b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783010?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15454000 U002 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783010/000114036121015121/amyt-20201231.xml#495793 Filing: 000114036121015121 Input fundies:CapitalExpenditure: 80000 U002 (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783010/000114036121015121/amyt-20201231.xml#2482693 Filing: 000114036121015121 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	Unavailable Not reported for this period.	−U002 37.47 million Exact value Exact value: -37472000 U002 2019-01-01 – 2019-12-31: -37472000 U002 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Amryt Pharma plc · 2019-12-31 Amryt Pharma plc (edgar:1783010) Operating Cash Flow: -37472000 U002 Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T21:26:28Z Snapshot: 38c0edc4ea668d290f812b45724871aa835a6a18bf39ab3bcb7b4c9043e6665b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783010/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=U002&dimensions= Input fundies:OperatingCashFlow: -37472000 U002 (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783010/000114036122016877/brhc10036778_20f.htm#2414008 Filing: 000114036122016877 The citation records this snapshot. The page link may show a newer release later.	U002 578,000 Exact value Exact value: 578000 U002 2019-01-01 – 2019-12-31: 578000 U002 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Amryt Pharma plc · 2019-12-31 Amryt Pharma plc (edgar:1783010) Capital Expenditure: 578000 U002 Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T21:26:28Z Snapshot: 38c0edc4ea668d290f812b45724871aa835a6a18bf39ab3bcb7b4c9043e6665b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783010/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=U002&dimensions= Input fundies:CapitalExpenditure: 578000 U002 (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783010/000114036122016877/brhc10036778_20f.htm#2427161 Filing: 000114036122016877 The citation records this snapshot. The page link may show a newer release later.	−U002 38.05 million Calculation and evidence -37472000 − 578000 U002 Exact free cash flow: -38050000 U002 2019-01-01 – 2019-12-31: -37472000 U002 · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 578000 U002 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Amryt Pharma plc · 2019-12-31 Amryt Pharma plc (edgar:1783010) Free cash flow: -38050000 U002 Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T21:26:28Z Snapshot: 38c0edc4ea668d290f812b45724871aa835a6a18bf39ab3bcb7b4c9043e6665b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783010?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -37472000 U002 (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783010/000114036122016877/brhc10036778_20f.htm#2414008 Filing: 000114036122016877 Input fundies:CapitalExpenditure: 578000 U002 (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783010/000114036122016877/brhc10036778_20f.htm#2427161 Filing: 000114036122016877 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	Unavailable Not reported for this period.	U002 26.89 million Exact value Exact value: 26891000 U002 2020-01-01 – 2020-12-31: 26891000 U002 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Amryt Pharma plc · 2020-12-31 Amryt Pharma plc (edgar:1783010) Operating Cash Flow: 26891000 U002 Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:26:28Z Snapshot: 38c0edc4ea668d290f812b45724871aa835a6a18bf39ab3bcb7b4c9043e6665b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783010/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=U002&dimensions= Input fundies:OperatingCashFlow: 26891000 U002 (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783010/000114036122016877/brhc10036778_20f.htm#2412873 Filing: 000114036122016877 The citation records this snapshot. The page link may show a newer release later.	U002 1.5 million Exact value Exact value: 1503000 U002 2020-01-01 – 2020-12-31: 1503000 U002 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Amryt Pharma plc · 2020-12-31 Amryt Pharma plc (edgar:1783010) Capital Expenditure: 1503000 U002 Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:26:28Z Snapshot: 38c0edc4ea668d290f812b45724871aa835a6a18bf39ab3bcb7b4c9043e6665b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783010/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=U002&dimensions= Input fundies:CapitalExpenditure: 1503000 U002 (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783010/000114036122016877/brhc10036778_20f.htm#2426040 Filing: 000114036122016877 The citation records this snapshot. The page link may show a newer release later.	U002 25.39 million Calculation and evidence 26891000 − 1503000 U002 Exact free cash flow: 25388000 U002 2020-01-01 – 2020-12-31: 26891000 U002 · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 1503000 U002 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Amryt Pharma plc · 2020-12-31 Amryt Pharma plc (edgar:1783010) Free cash flow: 25388000 U002 Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T21:26:28Z Snapshot: 38c0edc4ea668d290f812b45724871aa835a6a18bf39ab3bcb7b4c9043e6665b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783010?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 26891000 U002 (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783010/000114036122016877/brhc10036778_20f.htm#2412873 Filing: 000114036122016877 Input fundies:CapitalExpenditure: 1503000 U002 (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783010/000114036122016877/brhc10036778_20f.htm#2426040 Filing: 000114036122016877 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	Unavailable Not reported for this period.	U002 15.54 million Exact value Exact value: 15540000 U002 2021-01-01 – 2021-12-31: 15540000 U002 Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Amryt Pharma plc · 2021-12-31 Amryt Pharma plc (edgar:1783010) Operating Cash Flow: 15540000 U002 Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:26:28Z Snapshot: 38c0edc4ea668d290f812b45724871aa835a6a18bf39ab3bcb7b4c9043e6665b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783010/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=U002&dimensions= Input fundies:OperatingCashFlow: 15540000 U002 (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783010/000114036122016877/brhc10036778_20f.htm#2411739 Filing: 000114036122016877 The citation records this snapshot. The page link may show a newer release later.	U002 729,000 Exact value Exact value: 729000 U002 2021-01-01 – 2021-12-31: 729000 U002 Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Amryt Pharma plc · 2021-12-31 Amryt Pharma plc (edgar:1783010) Capital Expenditure: 729000 U002 Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:26:28Z Snapshot: 38c0edc4ea668d290f812b45724871aa835a6a18bf39ab3bcb7b4c9043e6665b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783010/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=U002&dimensions= Input fundies:CapitalExpenditure: 729000 U002 (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783010/000114036122016877/brhc10036778_20f.htm#2424942 Filing: 000114036122016877 The citation records this snapshot. The page link may show a newer release later.	U002 14.81 million Calculation and evidence 15540000 − 729000 U002 Exact free cash flow: 14811000 U002 2021-01-01 – 2021-12-31: 15540000 U002 · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 729000 U002 · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Amryt Pharma plc · 2021-12-31 Amryt Pharma plc (edgar:1783010) Free cash flow: 14811000 U002 Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T21:26:28Z Snapshot: 38c0edc4ea668d290f812b45724871aa835a6a18bf39ab3bcb7b4c9043e6665b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1783010?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 15540000 U002 (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783010/000114036122016877/brhc10036778_20f.htm#2411739 Filing: 000114036122016877 Input fundies:CapitalExpenditure: 729000 U002 (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1783010/000114036122016877/brhc10036778_20f.htm#2424942 Filing: 000114036122016877 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

59 filings · 330 latest values · 330 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001783010, 1783010, AMYT, edgar:1783010

Also known as Amryt Pharma Holdings Ltd, Amryt Pharma plc

Amryt Pharma plc

Latest fiscal year

Revenue

Operating margin

Operating cash flow

Free cash flow

Company performance

What changed year over year

Revenue

Operating cash flow

Capital expenditure

Where revenue goes

2021 2021-01-01 – 2021-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation